ELCO Management Co. LLC Invests $168,000 in Dynavax Technologies Corporation $DVAX

ELCO Management Co. LLC purchased a new position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in the 2nd quarter, Holdings Channel reports. The firm purchased 16,949 shares of the biopharmaceutical company’s stock, valued at approximately $168,000.

Several other hedge funds also recently made changes to their positions in DVAX. DekaBank Deutsche Girozentrale bought a new position in shares of Dynavax Technologies in the first quarter valued at $30,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Dynavax Technologies by 5,485.7% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,304 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Dynavax Technologies by 88.4% in the first quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 3,627 shares in the last quarter. Callan Family Office LLC bought a new position in shares of Dynavax Technologies in the second quarter valued at $107,000. Finally, Moloney Securities Asset Management LLC bought a new position in shares of Dynavax Technologies in the first quarter valued at $131,000. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Trading Down 0.3%

DVAX stock opened at $10.46 on Wednesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01. The company has a fifty day moving average price of $10.02 and a two-hundred day moving average price of $10.31. Dynavax Technologies Corporation has a one year low of $9.20 and a one year high of $14.63. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -22.74 and a beta of 1.13.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.02. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. The firm had revenue of $95.44 million during the quarter, compared to analysts’ expectations of $87.55 million. Equities analysts anticipate that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Insider Buying and Selling

In related news, Director Scott Dunseth Myers acquired 3,800 shares of Dynavax Technologies stock in a transaction on Friday, August 22nd. The stock was purchased at an average cost of $10.82 per share, with a total value of $41,116.00. Following the completion of the transaction, the director directly owned 35,004 shares in the company, valued at $378,743.28. This trade represents a 12.18% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.98% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DVAX. Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Finally, JMP Securities reissued a “market outperform” rating and issued a $32.00 target price on shares of Dynavax Technologies in a research note on Friday, August 22nd. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $24.33.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.